Progression-Free Survival (46.9 Month Follow up)1
Investigator-assessed PFS at 46.9 months median follow up1
- INV Assessed PFS
- INV Assessed PFS: Del(17p) and/or Mutated TP53
- INV Assessed PFS: Unmutated IGHV
- INV Assessed PFS: Mutated IGHV
INV Assessed PFS2
aHazard ratio was based on unstratified Cox-Proportional-Hazards model.
bP-value was based on unstratified log-rank test.
INV Assessed PFS: Del(17p) and/or Mutated TP531
aHazard ratio was based on unstratified Cox-Proportional-Hazards model.
bP-value was based on unstratified log-rank test.
INV Assessed PFS: Unmutated IGHV1
aHazard ratio was based on unstratified Cox-Proportional-Hazards model.
bP-value was based on unstratified log-rank test.
INV Assessed PFS: Mutated IGHV1
aHazard ratio was based on unstratified Cox-Proportional-Hazards model.
bP-value was based on unstratified log-rank test.
Abbreviations
A = acalabrutinib
;CI = confidence interval
;Clb = chlorambucil
;HR = hazard ratio
;IGHV = immunoglobulin heavy chain variable region
;INV = investigator
;NE = not estimable
;NR = not reached
;O = obinutuzumab
;PFS = progression-free survival
;TP53 = tumor protein 53
References
2. Inhouse data, AstraZeneca Pharmaceuticals LP. DoFP SD-2045-ALL-0098.
Document ID: 780f9b60-d375-4516-97d6-9ba58f025de4
Last updated: 17-April-2023
Disclaimers
Please note that this content may contain some data and/or patient populations which are considered off-label in your country. Providing this information does not constitute any recommendation for use. AstraZeneca is providing this material as an information service and professional courtesy.
©2023 AstraZeneca. All rights reserved.